INTRODUCTION
The molecular pathogenesis of acute myeloid leukemia (AML) has not yet been completely defined. Recurrent chromosomal structural variations (e.g., t(15;17), t(8;21), inv(16), t(9;21), t(9;11), del5, del7, etc.) are established diagnostic and prognostic markers, suggesting that acquired genetic abnormalities play an essential role in leukemogenesis (Betz and Hess, 2010) . However, nearly 50% of AML cases have a normal karyotype (NK), and many of these lack recurrent structural abnormalities, even with high density comparative genomic hybridization (CGH) or SNP arrays (Bullinger et al., 2010; Suela et al., 2007; Walter et al., 2009) . Targeted sequencing efforts have identified several mutations that carry diagnostic and prognostic information, including mutations in FLT3, NPM1, KIT, CEBPA, and TET2 (reviewed in (Bacher et al., 2010; Stirewalt and Radich, 2003) ). The advent of massively parallel sequencing enabled the discovery of recurrent mutations in DNMT3A (Ley et al., 2010; Yamashita et al., 2010) and IDH1 (Mardis et al., 2009) . Despite these efforts, more than 25% of AML patients carry no mutations in the known leukemia-associated genes . Furthermore, defining the molecular consequences of recurring mutations (e.g., whether a mutation is an initiating or a cooperating event) has been challenging.
PML-RARA is one of the best-characterized leukemia-initiating mutations. This fusion gene results from t(15;17)(q22;21) and is associated exclusively with acute promyelocytic leukemia (APL, FAB M3 AML) (Allford et al., 1999; Rowley et al., 1977) . Its expression is diagnostic of this single type of leukemia with unique clinical features (Sanz et al., 2009) . Its presence predicts a near universal therapeutic response to a targeted agent, alltrans retinoic acid (ATRA), which is abrogated by mutations that inhibit ATRA binding to PML-RARA (Imaizumi et al., 1998; Larson and Le Beau, 2011; Takayama et al., 2001) . Early myeloid expression of PML-RARA results in leukemia with promyelocytic features in multiple mouse models of the disease, although long latency (which can be shortened by radiation, alkylator treatment, or FLT3 ITD coexpression), suggests that PML-RARA requires cooperating events to cause leukemia (Funk et al., 2008; Kelly et al., 2002; Kogan, 2007; Sohal et al., 2003; Walter et al., 2004) .
In this study, we sequenced the genomes of 24 AML cases. We chose to compare 12 genomes from patients with FAB M3 AML (where the initiating event is known) to 12 genomes from patients with AML without maturation (FAB M1) with normal cytogenetics, where the initiating event is less clear for most patients. In this and previous studies, we have demonstrated that AML genomes generally contain hundreds of mutations, that the total number of mutations per AML genome is related to the age of the patient, and that nearly all AML cells in the samples contain all of the mutations (although very few of these mutations are recurrent in AML or other malignancies) Ley et al., 2008; Link et al., 2011; Mardis et al., 2009; Welch et al., 2011b) . We show here that clonally derived hematopoietic cells from normal individuals also accumulate mutations as a function of age. This suggests that most of the mutations present in AML genomes were already present in the hematopoietic cell that was "transformed" by the initiating mutation; nearly all of these preexisting mutations are probably benign and irrelevant for pathogenesis.
Consistent with this hypothesis, we observed that M1 and M3 genomes have similar numbers of total mutations and that M1 genomes contain unique mutations (e.g., DNMT3A, NPM1, IDH1, or TET2) that almost never occur in M3 cases. In addition, there are many mutations that are shared between the two subtypes (e.g., FLT3 ITD), suggesting that these mutations can cooperate with a variety of initiating mutations. Because the data are comprehensive for all 24 genomes, it also allows us to estimate the minimum number of recurring mutations that may be responsible for the pathogenesis of AML.
RESULTS

Whole-Genome Sequencing of 24 AML Samples
We subjected 12 cases of NK M1 AML and 12 cases of t(15;17)-positive M3 AML to whole-genome sequencing (WGS) (case descriptions provided in Extended Experimental Procedures, summarized in Table S1 and Figure S1 available online). To identify somatic, AML-associated mutations, we subjected both the bone marrow (leukemic tissue) and skin (normal tissue) to WGS (average haploid coverage 28x, Figure 1A and Table S2 ); the mutations in the AML1 and AML2 genomes have been previously reported and deposited in dbGaP Ley et al., 2008; Mardis et al., 2009) . They are included in this study for ease of reference. Because of the prevalence of false-positive calls in WGS (between 20%-50%, depending on the stringency of type I errors tolerated), we validated all single nucleotide variants (SNVs), small insertions and deletions (indels), and structural variants (SVs) identified in tiers 1, 2, or 3 (which contain the nonrepetitive portion of the genome (see Mardis et al., 2009 for definitions of tiers) by using patient-specific custom NimbleGen capture arrays, followed by Illumina sequencing (Figure 1B) . All subsequent analysis relies on these validated data and not on the primary genome discovery sequence. An average coverage of 972 reads per somatic variant was obtained at validation. We observed a higher validation frequency in tier 1 than in tier 2 and 3 (mean frequency 0.5 versus 0.35 and 0.29, p < 0.002 and p < 0.0001, respectively; Table S2 ), which may reflect the lower guanine and cytosine content and increased uniqueness of tier 1. Numbers of mutations and validation frequencies were similar across all tiers in M1 versus M3 genomes ( Figures 1C-1E and Table S2 ). These data yielded a total of 10,563 validated somatic variants for the 24 genomes (average 440/genome) (Tables S2, S3 , and S4). Indels were less frequent than SNVs in M1 and M3 AML (M1: average 19.1 per genome, range 4-45; M3: average 20.3 per genome, range 4-56), and occurred proportionally less often in tier 1 (average 1.4 per genome, range 0-4). Of these total somatic mutations, 319 occurred in the coding regions of 287 unique genes; an average of 10 somatic mutations had translational consequences in each genome (Table S3) . A fusion event between PML and RARA was identified in all 12 M3 AML cases (Table  S5) . Only 43 additional structural variants (translocations, insertions, deletions, and inversions) were identified (median 2 per genome, range 0-8, Table S5 ). The t(15;17) breakpoints occurred in exon 5 and introns 3 and 5 of PML and within RARA intron 2 in all cases, as expected; two cases were associated with large deletions that are predicted to result in PML-RARA expression without reciprocal RARA-PML expression ( Figure S2 ). None of the other structural variations found by WGS were identified with metaphase cytogenetics; most are predicted to be cryptic when examined by routine cytogenetics. The others may exist in minor leukemic subclones that were not otherwise detected, or in cells that did not expand during preparation for cytogenetic studies.
The total number of validated SNVs per genome increased in proportion to patient age, in both M1 and M3 AML genomes (Figure 1F) . We also observed that somatic AML mutations were widely distributed throughout the genome; in all 24 cases, the number of SNVs in each tier was directly proportional to the amount of the genome present in that tier (SNVs per Mb: tier 1: 0.264 ± 0.024; tier 2: 0.283 ± 0.026; tier 3: 0.283 ± 0.024, p < 0.91) ( Figure 2A ) and these mutations were distributed across all chromosomes ( Figure 2B ). However, with this sample size, modestly increased mutational frequency within small regions of the genome cannot be excluded ( Figures 2C and 2D) .
The mutational spectrum was dominated by C>T/A>G transitions, and was similar for M1 and M3 cases ( Figure 2E ). Tier 1 mutations favored C>T/A>G transitions, probably due to an increased proportion of methylated cytosine nucleotides in tier 1, which is associated with increased susceptibility to deamination and subsequent transition mutations ( Figure 2F ) (Pfeifer, 2006) .
For this study, skin samples were obtained when the patients presented with leukemia. As expected, we observed low-level contamination of leukemic variants in the skin samples, which was proportional to the peripheral white blood cell (WBC) count at the time of skin collection ( Figures S3A-S3C ). M3 AML cases usually had very low leukemia contamination in the skin (often completely absent), although we observed two outlier cases. There was no correlation between disproportionally high skin contamination and clinical history (e.g., leukemia cutis, gum hypertrophy, pulmonary hemorrhage, or intracranial hemorrhage). Clusters of mutations with similar variant allele frequencies within individual cases provide evidence of a single founding clone in both M1 and M3 samples . Using kernel density analysis, we identified one to four clusters of mutations (representing the founding clone in all cases, with or without additional subclones derived from the founding clone) in each genome ( Figures 3A-3D) ; the clusters were independent of the number of read counts for each SNV. In cases with subclones, the number of variants specific to each subclone was relatively small (an average of 40.4 SNVs per subclone [range 6-110]); SNVs in subclones represented only 14% of the total SNVs per genome (range 2%-33%). Because each genome's founding clone contains heterozygous SNVs that appear to be present in nearly all of the cells in the sample, subclones must also contain all of the SNVs in the founding clone. For example, the average variant frequency of heterozygous SNVs in the founding clone of AML13 ( Figure 3D ) is 44%, suggesting that 88% of the cells in the sample contain these heterozygous mutations; therefore, the subclones with average variant allele frequencies of 12%, 22%, and 32% must also contain the mutations found in the founding clone. Genomes with two or more mutation clusters displayed a similar standard deviation of variant frequencies within separate clusters ( Figure 3E ). However, genomes with a single cluster tended to have an increased standard deviation of the variant frequency within that cluster, suggesting that overlapping subclones may exist in these samples that are below this level of resolution. There was a trend toward more subclones in M3 cases (M1 average, 1.5 clones/genome; M3 average, 2.2 clones/genome; p = 0.04) ( Figure 3F ).
Several pieces of data suggest that most of the mutations in the founding clone may be random events that preexisted in the hematopoietic cell that acquired the initiating mutation: (1) the presence of hundreds of mutations in the founding clones of all AML genomes (which is far greater than the number expected to be biologically relevant), (2) their presence in nearly all of the AML cells in the sample, and (3) the correlation of the number of total mutations with the patient's age. We expect that an AML-initiating mutation would provide a growth advantage for an HSPC and that the preexisting, random mutations in that HSPC would therefore be ''captured'' in all its progeny when that cell clonally expands. Even though the preexisting mutations would not be pathogenetically relevant, they would be present in all of the cells in the founding clone, and appear as somatic mutations when the AML sample is sequenced. Although this hypothesis cannot be proven directly with current technologies, it strongly suggests that HSPCs derived from healthy people may acquire random, benign mutations as a function of age. This issue is addressed in the next section.
Identification of Background Mutations in Normal Human Hematopoietic Cells
To determine whether normal human hematopoietic cells accumulate mutations over time, we performed exome sequencing on the progeny of three different HSPCs from seven healthy individuals of different ages, and compared these sequences to those of normal peripheral blood from the same donors (which are thought to have contributions from $1,000 hematopoietic stem cells at any given time) (Abkowitz et al., 1996; Abkowitz et al., 2000; Catlin et al., 2011) . Details of the experiments are provided in Experimental Procedures and Figure S6 . We focused on mutations with variant allele frequencies of 50% (±2 SDs), which strongly suggests that they are present in all cells in the sample; mutations that are not present in all cells may have arisen during the outgrowth of the HSPCs in culture and would be artifacts of the ex vivo expansion. The number of validated mutations in each clonally derived sample was lowest in the cord blood samples and increased as a function of age (Figure 4A) ; in adult volunteers, the number of mutations detected in each exome was similar to that detected in AML patients of the same age. Each of the mutations was distinct for each of the clones ( Figure 4B and Table S6 ). The mutational spectrum was very similar to that of AML samples ( Figure 4C ); both have mostly transitions, suggesting that they may represent mutations caused by deamination of methylcytosine residues. Collectively, these data suggest that normal, self-renewing hematopoietic stem cells accumulate random background mutations as a function of age. These background mutations would therefore be present in all cells present in an AML founding clone, would increase with age, and would generally be irrelevant for AML pathogenesis.
Identification of Genes with Recurring Mutations
To better identify the recurrently mutated genes in the sequenced AML genomes, we extended the analysis to additional AML cases. A liquid-phase capture approach followed by Illumina sequencing was used to assess the mutational status of 284 of the tier 1 mutated genes in an additional 53 M1 and 31 M3 cases ( Figure S1D and Table S7 ). We also assessed the mutational status of 53 genes previously reported to be mutated in AML (see Extended Experimental Procedures). Forty-one of these cases did not have a matched normal sample. Among the 108 genomes assessed, we identified 23 genes containing mutations with translational consequences in at least 3 independent samples ( Figure 5A ). In the 24 cases subjected to WGS, we observed an average of $14.5 tier 1 mutations per genome (M1: 14.8 ± 1.9; M3: 13.3 ± 1.4; p = 0.5, Figure 5B ). Of those, there was an average of $3 recurrent mutations in each M1 genome (3.4 ± 0.7, range 0-7) versus 2 recurrent mutations in each M3 genome (2.2 ± 0.3, range 1-5, p = 0.1, including PML-RARA, Figure 5C ). Among the 108 total genomes assessed, there were an average of $2 recurrently mutated genes per M1 sample (M1: 2.2 ± 0.2, range 0-10) versus $2 genes per M3 sample (1.7 ± 0.1, range 1-4; p < 0.09, including PML-RARA, Figure 5D ).
Patterns of Recurrent Mutations in M1 versus M3 AML Genomes
We identified nine recurrently mutated genes found in both the M1 and M3 genomes (FLT3, TTN, NRAS, PKD1L2, CACNA1E, DNAH9, WT1, ANKRD24, and PHF6) ( Figure 5A ). Mutations in these genes may represent cooperating events that are capable of interacting with several different initiating mutations.
Thirteen genes were recurrently mutated only in M1 genomes (NPM1, DNMT3A, IDH1, TET2, IDH2, RUNX1, ASXL1, PTPN11, DIS3, KIT, SMC1A, SMC3, and STAG2) ( Figure 5A ), suggesting that they might be involved with AML initiation. Of this group, six had mutation frequencies that were statistically higher in M1 versus M3 patients (NPM1, p < 0.0001; IDH1, p < 0.0001; IDH2, p < 0.01; TET2, p < 0.001; DNMT3A, p < 0.0001; ASXL1, p < 0.03).
Mutations in three genes (NPM1, DNMT3A, and IDH1) coexisted only in M1 genomes. These genomes contained additional mutations that were also found in M3 genomes. Recurring mutations that co-occur with PML-RARA are likely to be cooperating mutations, rather than initiating mutations. This further suggests that mutations in NPM1, DNMT3A, and IDH1, are more likely to be initiating, rather than cooperating, events in M1 AML genomes.
We observed nonrandom associations of NPM1, DNMT3A, IDH1, and FLT3 mutations in M1 AML cases, as follows: NPM1+DNMT3A, p < 0.028; NPM1+IDH1, p < 0.011; NPM1+ FLT3, p < 0.014; DNMT3A+IDH1, p < 0.001; DNMT3A+FLT3, p < 0.04, similar to our previous report and to others ( Figure S7 ) (Ley et al., 2010; Marková et al., 2012; Shen et al., 2011) .
We extended these findings by examining mutational frequency data from whole-genome or exome sequencing studies of 131 additional AML cases that included all other FAB subtypes from the TCGA AML study ( Figure 5A and Table S3 ). Clone   ZNF827  HIST3H3  SCN1A  PSPC1  LOC401533  EIF2AK4  TRIP10  C12orf51  FRAS1  RPLP1P4  CPNE7  APOB  GABRR3  LOC116349  NCKAP1  RGL2  TRDN  TTN  CFHR5  EEF1AL7  FIGN  PCDH24  DNMT3A  GCS1  GRIA1  MAGEB18  TMEM140  ALMS1  C2orf62  C6orf142  MYH4  PCDH11X  SALL1  SPON1  ARHGEF1  C4orf19  CACNG7  DEGS2  DNAH1  ENSG00000248738  ENSG00000249466   FBXO47  PLCL1  EYA1  GCSH  GPRC5D  LOC100287442   NR2F6  POLR2B  RAB21  SUN1  THSD7B  ZFHX4  C9orf79  CLDN14  FBXW10  LRIT2  NOD1  OR4D11  PWP1  TFDP3  VCAM1  VTA1  AGAP3  CASS4  CDC25B  CENPE  FAM173B  KIAA1274  NEDD4L  NPFFR2  SYNE1  TRPM6  C2orf71  CARD10  COX19  DRD3  MAP1B  MDH1B  TAOK2  TPH1   1  2  1  3  1  1  2  1  3 Most of the genes (20/23) were recurrently mutated in these additional samples, suggesting that these mutations may participate in the pathogenesis of other AML subtypes, as expected. Some genes with low mutation frequencies in the M1 and M3 cases were not recurrently mutated in the 131 additional cases (e.g., ANKRD24, DIS3, and PML-RARA), but none of the differences were statistically significant. Three of the recurrently mutated genes, STAG2, SMC3, and SMC1A, are members of the cohesin complex, which is a tetrameric structure that also includes RAD21; this complex is involved in sister chromatid separation during anaphase, and CTCF-mediated chromatin topologic constraints (Carretero et al., 2010; Millau and Gaudreau, 2011) . STAG2 was recently found to be deleted in an AML genome (Walter et al., 2009) and in cancer cell lines (Rocquain et al., 2010; Solomon et al., 2011) . We therefore assessed all four genes for mutations in a larger set of 183 AML samples subjected to exome or whole-genome sequencing as a part of The Cancer Genome See also Figure S6 and Table S6.   M2  M1  M5  M2  M4  M2  M2  M2  M1  M1  M0  M1  M2  M1  M2  M2  M2  M2   750152  933124  730817  433325  245450  100232  570755  905179  982009  123172  275382  150288  179223  831711  103342  463352 M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M3  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1  M1   PML-RARA  44  0  NA  NA  NA  FLT3  35  29 Table S7 .
Atlas (TCGA) study of AML (T.J.L., and R.K.W., unpublished data). We identified mutations in all four cohesin complex genes, whereas the related genes STAG1 and STAG3 were not mutated ( Figure 5E ). These mutations were not detected in any M3 genomes. Of the 19 mutations identified in cohesin complex genes, 11 had loss-of-function consequences (nonsense, splice site, or gene deletions). Two cohesin complex genes are found on the X chromosome, and mutations in those genes were identified in six male patients. Cohesin complex gene mutations were not associated with chromosomal instability (Solomon et al., 2011) ; 12 of the cases with cohesin mutations had normal cytogenetics, six had three or fewer cytogenetic abnormalities, and only one had complex cytogenetics. We examined the expression of all of the recurrently mutated genes by using expression array data for all of the M1 and M3 cases available in our data set ( Figure 5A and Table S3 ). The expression values of all probe sets on these arrays are normalized to an average chip mean of 1,500. Most of the recurrently mutated genes are highly expressed in both M1 and M3 AML cases. Several of the genes had very low expression levels (e.g., TTN, PKD1L2, ANKRD24, CACNA1E, and DNAH9) on the Affymetrix U133 Plus 2 array. Using readcounts from RNA-Seq data obtained from 155 AML cases from the TCGA study of AML, we were able to show that spliced transcripts from TTN and ANKRD24 are detected in virtually all AML samples tested, whereas PKD1L2, CACNA1E, and DNAH9 transcripts were absent in all (or nearly all) of the same samples. We suggest that mutations in genes that are not detectably expressed are less likely to be relevant for pathogenesis.
We identified only two germline variants that were likely to be relevant for AML pathogenesis: WT1 R430* in AML15 (age 25), and PTPN11 Y197* in AML9 (age 25). These data are presented in the Extended Experimental Procedures and Table S8 .
Integration of Coexisting Variants within Individual Patients
Mutations that may be relevant for AML pathogenesis are integrated for all 24 fully sequenced patients in Table 1 . This analysis identified at least two likely AML driver mutations (in genes that are recurrently mutated in AML and/or other cancer types and expressed in the patient's own AML sample) in 23 of 24 cases and at least 4 likely drivers in 15 of 24 cases. This outcome is consistent with our predicted statistical power from this experimental design and sample size (see Extended Experimental Procedures). These mutations are organized into currently annotated pathways (Figure 6 ), which reveal potential relationships among genes that are infrequently mutated in this set of cases.
DISCUSSION
In this report, we describe the comprehensive sequencing of the entire genome of 24 carefully selected acute myeloid leukemia cases. Paired-end sequencing of the entire tumor and normal skin genomes was performed for each case, along with independent validation of all putative mutations identified in the nonrepetitive part of the human genome. We compared the genomes of patients with a known initiating mutation (PML-RARA) with genomes that have less known about the initiating events (AML without maturation-FAB M1 with normal karyotype). Both AML subtypes have approximately the same number of overall mutations in their genomes, and both are associated with relative genomic stability (in all cases we observed a small number of total SNVs, indels, and SVs, compared with most solid tumors). The SNVs were distributed across the entire genome, and the mutational spectrum of SNVs was virtually identical between the two AML subtypes. By comparing these two subtypes of AML, we were able to distinguish the mutations that are likely to be initiating events in the cytogenetically normal cases, versus the cooperating events that are common to both subtypes; this analysis suggests that mutations in NPM1, DNMT3A, and IDH1 may act as major initiating mutations in M1 AML.
We found a small number of mutations with translational consequences (e.g., nonsynonymous mutations in tier 1) in each of the 24 genomes: the average was $11 for M1 AML and $10 for M3 AML (including the PML-RARA fusion event). Only a portion of these mutations were found to be expressed in the patient's sample and recurrent in other M1/M3 AML genomes, yielding a median number of three recurring mutations in M1 genomes, versus two in M3 genomes (including the PML-RARA fusion). Additional mutations are likely to contribute to pathogenesis (such as mutations that occur with <3% frequency in AML or that occur in solid tumor-associated genes), although their biological significance in AML is less certain (Table 1 and Figure 6 ).
These data, because they were derived from completely sequenced genomes, allow us to estimate the minimum number of genic mutations that may be required for AML pathogenesis. We observed one M3 AML genome in which the only detected recurrent AML or cancer-associated tier 1 somatic mutations were PML-RARA and FLT3 ITD (AML9; Table 1 and Figure 6 ). In mice, this combination of mutations can cooperate to accelerate the onset (or development) of AML with many of the features of acute promyelocytic leukemia (Kelly et al., 2002; Sohal et al., 2003) . Furthermore, by sequencing an APL genome-derived from a mouse expressing human PML-RARA, we recently defined a recurring, spontaneous mutation in the Jak1 gene at position V657F (Wartman et al., 2011) ; this mutation that is identical to that found in some human patients with B lymphoblastic leukemia (Flex et al., 2008; Harvey et al., 2010; Mullighan et al., 2009 ) and a patient with M3 AML (Jeong et al., 2008) . When this Jak1 mutation was coexpressed with PML-RARA in mice, the animals developed an explosive, oligoclonal APL syndrome within 4 weeks, strongly suggesting that these two mutations were sufficient to produce the disease (Wartman et al., 2011) . These data support the idea that as few as two key somatic mutations may cause AML in some patients.
We observed that human hematopoietic stem/progenitor cells (HSPCs) from healthy volunteers each contain private mutations that accumulate as a function of age; we calculated that 0.13 ± 0.02 exonic mutations are acquired per year of life ( Figure 4A ). Current models of human hematopoietic stem cells (HSCs) suggest that one cell division occurs every 25-50 weeks (Catlin et al., 2011) . Experimental methods of interrogating human HSC turnover are, however, somewhat limited. Murine HSC division rates are better characterized, and the data Gene expression R800 by Affymetrix U133 Plus2 array (chip mean 1,500). Gene expression <800 by Affymetrix U133 Plus2 array (chip mean 1,500).
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suggest that murine HSCs fluidly transition between two pools, one cycling every 2-6 weeks and a second cycling every 20-50 weeks (Foudi et al., 2009; Takizawa et al., 2011) . DNA replication fidelity rates have been measured between 0.06-1.5 3 10 À9 , depending on cell type (germ cells have the highest fidelity, and cells grown in tissue culture have the lowest) (Gundry and Vijg, 2012; Lynch, 2010) . Therefore, if HSPCs have a fidelity rate of 0.78 3 10 À9 mutations per genomic base pair per cell division (midway between the fidelity of germ cells and cells in tissue culture), and undergo 2-20 divisions per year, we would predict that they would acquire between 0.069-0.858 exonic mutations per year. The mutation rate we have measured is within the expected parameters, which are based on our current understanding of replication fidelity and HSPC cell division rates. These data provide a plausible explanation for the large number of unique background mutations in each AML genome. These data are consistent with previously described models of oncogenesis (Figure 7 ) (Armitage and Doll, 1957; Calabrese et al., 2004; Loeb et al., 1974; Nowell, 1976; Tomlinson et al., 1996) . In the first step of leukemogenesis, a driver mutation (e.g., PML-RARA or NPM1) occurs within the context of an HSPC that already contains hundreds of random, benign mutations that have accumulated over time. This mutation confers an advantage to this cell, and as a consequence, all of the random background mutations within its genome (passengers) are ''captured'' and are carried forward as the clone expands. When an additional driver mutation (e.g., FLT3 ITD) occurs within a cell in an expanding clone, any additional passenger mutations that have accumulated in that cell (since acquisition of the first driver mutation) also will be captured. Eventually, these cells become the ''founding'' clone that is detected at presentation, which contains only a few drivers, but many passengers that were captured at initiation and a few additional passengers that were captured as cooperating events were added. Each progression event (and/or events that contribute to subclone outgrowth) probably yields a small cluster of new mutations, of which only one or two may be relevant for clonal outgrowth. Our data suggest that the number of additional passengers added with progression events is typically much smaller than the number of passengers captured with the initiating event (which accumulated over the lifetime of the founding cell).
The 13 recurrently mutated genes that are found only in M1 samples may be involved in the initiation of M1 AML. Mutations in NPM1, DNMT3A, and IDH1 occur only rarely in M3 genomes (Ley et al., 2010; Lin et al., 2011; Shen et al., 2011) , and co-occur more often than can be explained by chance (Ley et al., 2010; Marková et al., 2012; Shen et al., 2011) . This pattern suggests that mutations in these genes may sometimes cooperate to initiate AML and that this is likely to be a central AML pathway, around which rare and private mutations can coalesce. No patterns of cooperation could be discerned between the other recurrently mutated genes that are M1-specific, except for mutations in the genes that encode members of the cohesin complex, which will be discussed below.
Nine recurrently mutated genes were detected both in M1 and M3 genomes, suggesting that these mutations may cooperate with a variety of initiating events to produce the disease. By far the most frequently mutated gene in this set is FLT3, where M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3   PML-RARA  NPM1  DNMT3A  IDH1  TET2  SMC3  SMC1A  STAG2  WT1  PHF6  ETV6  CEBPA  IKZF1  FLT3  ABL1  AURKB  EPHA8  DDR2  PRKRA  RBKS  WNK4  EPHB1  NRAS  PTPRT  PTPN11  PTPRG  GPR183  PCDH24  GPR123  CELSR1  ARHGAP5  MYH14  SOS1  AKAP13  GBP4  MPND  TRIM24  LBXCOR1  MED14  CAMTA1  EWSR1  AFF2  CNOT3  HIVEP1  RUFY1  MAX  TTLL5  C5orf25  ZFHX3  ZNF687  ZNF788  TRPC1  TRPM4  PKD1L2  FREM2  ATP9B  CACNA1E  CACNA2D3  MUC5B  OVGP1  UNC5B  SRCRB4D  ODZ2  SDK2  CNTN5  VCAM1  SLC15A1  SLC24A3  ABCA10  SI  USP44  USP9X  CUL3  MYCBP2  HERC1  MAP1B  DCTN1  DNAH9  TTN  CEP170  LAMA5  NAV1  C19orf62  RFC1  DIS3  TOP3B  PRPF8  SHQ1  SRRM2  BMS1  ARID2  KAT2B  WAC  MLL3-BAG2  PAPPA2  EGFL8  PDXDC1  DCT  NOS1  MLC1  KRTAP26-1  EPB41L5  ANKRD24  LRRC37B  FAM5C  OR4C15  DAGLB  C1orf168  BICD1  COL11A2  LOC100133292  KIDINS220 internal tandem duplications are known to cooperate with other initiating events in mice to produce disease progression, but do not initiate leukemia on their own (Kelly et al., 2002; Li et al., 2008; Sallmyr et al., 2008) . Although several groups have suggested that an activated tyrosine kinase may be an essential feature of all AML cases (Gilliland, 2002; Ishikawa et al., 2009; PedersenBjergaard et al., 2008; Zheng et al., 2009 ), we identified mutations in alternative tyrosine kinase genes in only 1 of the 13 completely sequenced genomes that lacked a FLT3 mutation (AML10, which contained both ABL1 P937L and DDR2 M291I).
In the entire set of 108 cases, we observed mutations in tyrosine kinase genes in only 5 of the 69 genomes that lacked a FLT3 mutation (these four additional cases had somatic variants in KIT D816V and D816Y, JAK2 V617F, and DDR2 G222R). We had previously addressed this possibility by sequencing the expressed tyrosine kinases in AML cases (Tomasson et al., 2008) ; however, that study was limited by the fact that only targeted gene sequencing was performed. Here, where whole genomes were sequenced, we are more confident that a second mutated tyrosine kinase gene is not required for most cases of AML. However, it is possible that mutations in protein phosphatases and G protein receptor/modulators might substitute for kinase mutations in some cases ( Figure 6 ). We identified recurring mutations in the genes that encode all four members of the cohesin complex (STAG2, SMC3, RAD21, and SMC1A), a set of proteins that assemble into a ring structure that encircles sister chromatids during metaphase, maintaining their polarity during mitosis (Carretero et al., 2010; Millau and Gaudreau, 2011) . The cohesin complex mutations occurred in $10% of non-M3 AML cases and co-occurred with NPM1, DNMT3A, TET2, or RUNX1 mutations in 17/19 cases. Eleven of these cohesin mutations were predicted to cause loss-of-function for the affected gene; STAG2 and SMC1A are both on the X chromosome, and null mutations in these genes are predicted to create complete protein deficiency for the three male patients with these mutations. All of the mutations were mutually exclusive of one another, suggesting that an alteration of only one component of the complex may be sufficient to disrupt or alter the entire complex. Recently, loss-of-function mutations in the STAG2 gene were shown to be associated with aneuploidy in cancer cell lines derived from solid tumors (Solomon et al., 2011) ; however, only 1 of the 19 AML genomes with cohesin complex mutations was aneuploid. Although we do not yet understand the mechanisms by which these mutations may contribute to AML pathogenesis, the discovery of recurrent mutations in the genes encoding this important structure represents yet another pathway that is undoubtedly relevant for this disease.
Although we have focused this report on recurrently mutated genes, we have also identified 15 recurrently mutated nongenic regions (e.g., mutations occur within 100 base pairs of one another) within these 24 completely sequenced genomes. We previously reported one identical mutation in two AML genomes, falling in a conserved but unannotated portion of the genome (Mardis et al., 2009 ). None of the 15 recurrent mutations identified here was associated with altered expression of its nearest neighbor gene, and none occurred within 10,000 base pairs of an annotated, untranslated RNA (data not shown). As additional AML genomes are sequenced, the identification of significantly mutated regions may suggest functional properties for these unannotated parts of the genome (e.g., cryptic genes or transcribed regions, or regulatory domains).
In summary, we have been able to provide important insights into the origin and evolution of AML mutations with wholegenome sequencing. Although many AML mutations have been discovered by sequencing more limited parts of the genome, candidate gene sequencing and/or exome sequencing cannot provide enough information to confidently predict the full Hematopoietic stem/progenitor cells (HSPCs, shown in green) accumulate random, benign background mutations as a function of age. ''X'' represents these background mutations in the HSPCs, and may range from $100 to 1,000 events, depending on age. The initiating mutations are different for M1 AML cases and M3 AML cases. Because the initiating event provides an advantage for the affected cell, clonal expansion ensues, so that all of the preexisting mutations in that cell are ''captured'' by cloning. Each cooperating mutation gives the expanding clone an additional advantage; our data suggest that 1-5 events contribute to progression in most cases of AML. Each cooperating mutation is expected to capture all mutations that occurred between the initiating event and the progression event (designated as ''Y'' in the yellow cell). Although this number is unknown, the analysis of clonal progression of secondary AML (Walter et al., 2012) suggests that each cooperating mutation may capture dozens to hundreds of mutations. The ''founding'' AML clone is designated in red. Subclones arise from the founding AML clone by acquiring a small number of additional mutations that confer an advantage to that cell, along with any additional background mutations that may have occurred in the interim (represented as ''Z''). In this study, the average number of mutations captured in subclones was 40 (range 6-110). spectrum of mutations required for disease in an individual patient or to determine the global genomic character of a disease. Our data suggest that most of the somatic events in AML genomes appear to be random, preexisting, background mutations in the hematopoietic cell that acquired the key initiating mutation. This event ''captures'' the mutational history of this cell as it evolves to become the founding clone at presentation (we have recently reported a similar phenomenon when fibroblasts are cloned via reprogramming to become induced pluripotent stem cells ). Only a tiny fraction of the total mutations in each AML genome are therefore likely to be relevant for pathogenesis, for disease classification, and for targeted therapy. The comprehensive analysis of AML genomes, although technically complex, has therefore suggested that AML is not a disease caused by hundreds of mutations, but only a few. These data may have implications for the origins of mutations in other cancer types as well.
EXPERIMENTAL PROCEDURES
Whole-Genome Sequencing and Somatic Mutation Discovery Whole-genome sequence data were generated by using Illumina GA and Illumina GA IIx instruments Mardis et al., 2009 ). Paired-end reads 50À100 bp in length were aligned to NCBI 36 by using Maq (v0.6.8 or v0.7.1) or BWA (v0.5.5). Target haploid reference coverage was a minimum of 253 for tumor and 203 for normal. Sample specific variants were called by using MAQ (v0.6.8) or Samtools (r320, r453, or r599). Somatic SNVs were identified by using SomaticSniper as previously described Larson et al., 2012) . Somatic indels were detected as previously described . We used Pindel in both tumor and normal and selected only tier 1 Pindel predictions regardless of filtering (could be germline or somatic) for validation.
Somatic structural variants were identified as previously described by using BreakDancer; structural variant predictions were not filtered based on assembled sequence data from breakpoint flanking regions Ding et al., 2012) . Further detail provided in Extended Experimental Procedures.
All sequence variants for the AML tumor samples from 24 cases have been submitted to dbGaP (accession number phs000159.v3.p2).
Capture Validation and Analysis
Capture validation and analysis were performed as previously described .
Mutation Cluster Analysis
Tumor clonality estimates were determined as described previously . Briefly, supporting readcounts from custom capture validation data for somatic mutations in regions of diploid copy number (2N) with a minimum reference coverage >1003 were input into a custom R function that drew a kernel density estimate (KDE) plot and estimated the number and relative composition of clones in these tumors.
Extension Sequencing and Analysis
Nimblegen Liquid phase custom capture reagents were used to extend putative variant calls from the initial M1/M3 discovery data. These variants were extended on an additional set of samples including 53 M1 and 31 M3 cases. The target regions included 522 genes, 9 noncoding regions that had mutations in more than one discovery sample, and 24 identity SNP sites, and additional genes with ambiguous mutations. This final design space was 4.6 Mb. DNA Libraries were constructed by using ligation of Illumina adaptors to sheared whole-genome amplified DNA. A Solid Phase Reversible Immobilization (SPRI) bead cleanup procedure was conducted to select size fractions between 300 and 500 bp. Hybridizations were performed by using a customized version of the Nimblegen EZ exome protocol. Barcoding adaptors were used to enable postcapture multiplexing of 15 samples per lane on the sequencing instrument. qPCR was used to determine the quantity of captured library necessary for loading on a single lane of an Illumina Hi-Seq 2000 (2 3 100 bp) PE sequences in order to produce $2 Gbp of sequence/ sample.
Differential Mutation Frequency Analysis across Subtypes
RNA expression analysis of AML cases and flow sorted normal bone marrow was performed with Affymetrix U133 Plus2 arrays and has been previously published; Geo accession number GSE12662 ).
RNA-seq-Based Expression Analysis RNA-seq data for 155 TCGA AML tumor samples consisting of of 50 bp pairedend reads, were extracted from BAM into FASTQ format by using Picard 1.31 (http://picard.sourceforge.net/) and subsequently aligned by using the Tophat 1.1.4 release (Trapnell et al., 2009 ). Cufflinks 0.9.2 (Trapnell et al., 2010) was used to estimate expression levels for all known UCSC genes and transcript isoforms. The resulting transcript abundance estimates are expressed in fragments per kilobase of exon per million fragments mapped (FPKM), as proposed by Mortazavi et al. (Mortazavi et al., 2008) .
Exome Sequencing of Normal Volunteer Samples
Flow sorted CD34 + CD38 À lineage À cells were expanded on AFT024 stromal cells. DNA from individual colonies was prepared, captured with Agilent SureSelect Human All Exon v2 kit, and sequenced by using similar methods as we have published Mardis et al., 2009; Welch et al., 2011b ). Experimental details are described in Extended Experimental Procedures.
Statistical Analysis
Students t test, Wilcoxon comparison, ANOVA, log-rank, and hypergeometric distributions were used to compare results from two cohorts (Prism, GraphPad, La Jolla, California, and Excel, Microsoft, Seattle, Washington). The expected Poisson distribution was generated by using WinPepi (Abramson, 2011) .
ACCESSION NUMBERS
The database of Genotypes and Phenotypes (dbGaP) accession number for the AML tumor sequence variants is phs000159.v3.p2.
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